Tillkännagivande • Jun 11
Sona Nanotech Inc. Announces Appointment of Michael A. Fleming to Board of Directors Sona Nanotech Inc. had appointed Michael A. Fleming to the board of directors of the Company. Michael A. Fleming served as Executive Vice President for commercial operations and subsequently as Chief Strategy Officer of Coherus BioSciences. During his tenure with Coherus, he led the company's transformation from a development-stage organization into a commercial oncology business, architecting the commercial strategy and launch of UDENYCA (pegfilgrastim-cbqv), Coherus's first oncology asset and a market-leading pegfilgrastim brand. Earlier in his career, Mr. Fleming held senior leadership roles at Elan, Genentech, and GlaxoSmithKline, where he directed global commercial strategy across multi-billion-dollar franchises and led numerous product launches across oncology, infectious disease, metabolic and specialty therapeutics. Tillkännagivande • May 07
Sona Nanotech Inc Announces Clinical Strategy with Two THT Combination Therapy Studies in Melanoma Sona Nanotech Inc. announced its clinical strategy to further the development of its Targeted Hyperthermia Therapy ("THT") cancer treatment. Based on both the success of Sona's first-in-human clinical study with THT, which demonstrated its ability to shrink and prime tumors immunogenically when used alone, and the published results from preclinical testing of Sona's THT showing the higher and more durable response rates that were observed when THT is combined with standard immunotherapies, the Company now intends to trial advanced applications of THT in two innovative clinical studies in melanoma patients combining THT with immunotherapy drugs. Sona will undertake its next clinical study of THT, (the "IGNITE-THT Study" - Immunotherapy + THT to Generate Novel Immune Tumor Eradication). In this study, Sona's THT would be administered in conjunction with a regimen of intratumoral and systemic dosing of the same immunotherapy drugs on which a cohort of patients had previously failed. The IGNITE-THT Study is expected to demonstrate the same safety and tolerability as experienced in the Company's previous clinical study, but with enhanced efficacy and long-term durability from the combination therapy anticipated after tumors are immunogenically activated by Sona's THT treatment. A second study, (the "PRIME-THT Study" - Precision Regional Immunotherapy for Melanoma Enhanced by THT) will assess the same concept but in newly diagnosed early-stage melanoma sufferers, which represents a much larger number of affected people worldwide (estimated by management to be up to 275,000 globally each year). Patients in this study would be given THT in combination with intratumoral immunotherapy with a view to stopping tumors from spreading (metastasising) by THT activating strong immune responses prior to standard-of-care surgical tumor resection. In addition to evaluating the safety and tolerability of Sona's THT treatment in an 'up-front' (neo-adjuvant) setting, the PRIME-THT Study will also measure the immediate treatment effect and the long-term durability of responses related to this novel, early-stage, neo-adjuvant combination therapy. These new studies are designed to answer the same questions from different ends of the patient journey: can THT convert immunogenically 'cold' tumors into tumors that respond to immunotherapies? The IGNITE-THT Study will ask it for patients who have already failed on treatment and remain on immunotherapy's treatment plateau. The PRIME-THT Study asks it earlier, enabling and bringing the benefits of immunotherapy forward into the pre-resection window, where stopping metastases is still possible. Early result read-outs from the IGNITE-THT and PRIME-THT studies are expected within six and eight months of their initiation, respectively. An expansion to a second cancer indication. Demonstrating THT in both early and late-stage melanoma indications shows a greater breadth of potential treatment market size. Two near-term valuation catalysts. A clear strategy to demonstrate long-term potential to the investment community with relatively near-term deliverables. Potential for greater chances of cure. Priming tumors with THT to engage the immune system prior to the administration of today's best immunotherapy drugs could result in higher response rates to those drugs. Potential for reduced risk of metastases. Pre-treating early-stage melanoma tumors could reduce the chances that the cancer spreads to lymph nodes prior to standard-of-care resection. The Company also continues to lay the groundwork for a larger scale, clinical trial in Canada for late-stage melanoma patients, working with Health Canada to secure the required investigational testing authorization ("ITA"). Feedback received from Health Canada is guiding the Company's ITA application for a combination strategy clinical trial which it expects to begin early in 2027 and run for up to 18 months with multiple read-out milestones. Tillkännagivande • Apr 28
Sona Nanotech Inc. Showcases Targeted Hyperthermia Therapy Cancer Treatment Results At Industry Conferences Sona Nanotech Inc. announced that its Chief Medical Officer presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research last week in San Diego. The presentation highlights the initial safety, tolerability and anti-tumor activity from this study which demonstrated a complete response in treated indicative tumors in six out of ten late-stage melanoma patients who had previously failed on standard of care immunotherapy. This study is a critical milestone in the Company's mission to treat immunotherapy-resistant solid tumors in humans. A manuscript detailing these results is currently being prepared for submission to a leading peer-reviewed scientific journal. Sona's first-in-human study results speak to a persistent unmet need that remains the dominant conversation in the melanoma community. The Melanoma Research Alliance noted in October 2025 that roughly half of advanced melanoma patients still do not respond to -- or develop resistance to -- currently approved immunotherapies. Sona's study was conducted in patients from precisely this refractory group. Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. Sona's Targeted Hyperthermia Therapy (THT) uses proprietary gold nanorods that absorb infrared light to deliver precise heat directly to a tumor. This therapeutic heating (42-48°C) is designed to stimulate the immune system, shrink tumors, inactivate cancer stem cells, and increase blood flow to the site. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. Tillkännagivande • Apr 18
Sona Nanotech Inc. Announces Appointment of Dr. Michael Smylie and Dr. Jonathan Trites to Its Scientific Advisory Board Sona Nanotech Inc. announced the appointment of two renowned oncologists to its scientific advisory board: Dr. Michael Smylie and Dr. Jonathan Trites. Dr. Michael Smylie is a leading medical oncologist at the Cross Cancer Institute in Edmonton and a clinical professor at the University of Alberta, renowned for his transformative work in melanoma research. He played a key role as a contributing investigator and co-author in the landmark CheckMate clinical trials--specifically CheckMate 067. This study is hailed as a turning point in oncology, as it proved that combining immunotherapy drugs could lead to long-term survival for patients with advanced melanoma, a condition once considered a terminal diagnosis. His work on the long-term outcomes and quality-of-life data from these trials has helped establish the current international standard of care, moving the needle from short-term treatment to the possibility of decade-long remission for many. Dr. Jonathan Trites is a head and neck oncologic and reconstructive surgeon based at the Queen Elizabeth II Health Sciences Centre in Halifax. As an Associate Professor at Dalhousie University, he has been a key figure in research advancing surgical techniques and outcomes for complex head and neck cancers. Dr. Trites's work primarily focuses on improving the precision and functional outcomes of cancer surgeries. He is a leader in using minimally invasive techniques for tumors of the upper aerodigestive tract. His research has demonstrated that Transoral Laser Microsurgery (TLM) is a viable option for advanced-stage glottic cancer, achieving high rates of laryngeal preservation and excellent functional outcomes. He has also published significant data on various squamous cell carcinomas, including early-stage laryngeal cancer and oropharyngeal cancer. Tillkännagivande • Apr 14
Sona Nanotech Inc. Provides Follow-Up Histology Tissue Analysis Data from Clinical Cancer Study Sona Nanotech Inc. had provided follow-up histology tissue analysis data from its first-in-human early feasibility study of its Targeted Hyperthermia Therapy ('THT') in late stage melanoma patients who had failed on standard immunotherapy protocols (the 'Study'). An extensive multiplex histological tissue analysis conducted at Dalhousie University of representative tissues from Study patients showed extensive natural killer cell infiltration in tumor tissues biopsied after treatment with THT indicative of innate immune activation. Also, analysis of samples from Study patients who only partially responded to the THT treatment showed a significant increase in T-regulatory cells and strong PD-L1 expression suggesting that these tumors may benefit from adding PD-1 immunotherapy in combination with Sona's THT treatment. These results, together with pre-clinical modelling studies, give confidence that immunotherapy response rates, which are typically below 20% for colorectal cancer, can be increased by first priming tumors with Sona's THT therapy before administering immunotherapy. This histology tissue analysis, together with the Study's protocol and other findings are now being prepared for submission to a scientific journal for peer review and publication. In the Study, ten advanced-stage melanoma patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early feasibility study. Under the study protocol, patients had up to four tumors treated with Sona's THT on days one and eight of the Study. By day 15, 8/10 patients experienced a clinical response to the THT treatment with a majority (6/8) showing no detectable residual melanoma in representative, biopsied tumors, with two patients showing no response. Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ('CTAB') free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. Tillkännagivande • Apr 10
Sona Nanotech Inc Announces Preclinical Study Results for Targeted Hyperthermia Therapy in Combination with Immunotherapy Sona Nanotech Inc. had announced publication of a preclinical study using its Targeted Hyperthermia Therapy to treat cancer, in the Journal of Nanobiotechnology which demonstrated treatment durability to the end of the 45 day study period when it was given in combination with immunotherapy. Building on its prior body of preclinical research treating melanoma and breast cancer, this study was conducted in an immunologically 'cold' colorectal cancer (CT26) tumor model. In this combination protocol, CT26 tumor-bearing animals were treated with two consecutive treatments of Targeted Hyperthermia Therapy plus standard PD-1 inhibitor immunotherapy followed by three additional PD-1 treatments. Animals were followed for 45 days following initiation of treatment as per study protocol. At completion of the study 38% of animals given the combined therapy were alive and disease free. In this study, where no animals responded to a standard immunotherapy alone, 100% of animals in the Targeted Hyperthermia Therapy treatment group responded to that same immunotherapy. 38% (8 of 21) of those tumors completely cleared by day 24 following initiation of treatment and remained cancer-free to the end of the study. Targeted Hyperthermia Therapy is a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona Nanotech's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Sona Nanotech has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona Nanotech's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA. Tillkännagivande • Mar 05
Sona Nanotech Inc., Annual General Meeting, Apr 29, 2026 Sona Nanotech Inc., Annual General Meeting, Apr 29, 2026. Location: nova scotia, halifax Canada Tillkännagivande • Jul 07
Sona Nanotech Inc. Announces First Dosing Has Been Achieved in the Previously Announced Early Feasibility Study of Its Targeted Hyperthermia Therapy Cancer Treatment Sona Nanotech Inc. announced that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment. The study is designed to assess THT's safety, tolerability, and preliminary efficacy as measured by tumor growth inhibition and the extent to which it causes immune system engagement with the cancer. The study includes two treatments of Sona's THT, one week apart, for patients with advanced melanoma who are, or have been on, standard of care immunotherapy protocols but have failed to respond or progressed during treatment. The study is anticipated to generate an initial read out of results this summer, with final results expected in the fall. Technology will be evaluated for: Ease of setting up and preparation for the treatment. Ease of administration of GNR's in a variety of different tumors.roducibility in the clinical setting, i.e. the ability to train others to use the technology. Resource requirements, i.e. what additional resources are required in the clinical setting. Time required to administer the treatment in the clinical setting. Participants will be evaluated for: tolerability to the treatment itself. Adverse events during and following treatment. Tillkännagivande • Jun 29
Sona Nanotech Inc. Announces Ethics Committee Approval for Melanoma Clinical Trial Sona Nanotech Inc. announced that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment. The study is designed to assess safety, tolerability, and preliminary efficacy and will include two treatments of Sona's THT, one week apart, for patients with advanced melanoma who are on, but have failed to respond to, a standard of care immunotherapy protocol. The study is anticipated to be conducted this summer with an initial read-out of final results expected by September, subject to enrollment rates. Tillkännagivande • May 29
Sona Nanotech Inc. Successfully Completes FDA- Required Toxicity Study Sona Nanotech Inc. announced positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET Inc. This study indicates Sona's gold nanorods were well tolerated, with no signs of acute or systemic toxicity at 100 times the proposed clinical dosage level expected to be administered in humans with Sona's THT cancer therapy for melanoma. Given this safety profile, clinicians have reason to be excited about the prospects for this therapy as a less harmful potential alternative to immunotherapy drugs that can help patients but have toxicity issues with associated side effects. Next, The company expects these preclinical safety study results to provide significant comfort to regulators when considering applications for clinical trials in which will seek to establish THT's efficacy. The study evaluated the safety, tolerability, and tissue distribution of Sona's nanoparticles in three cohorts of twenty rats each at different dosage levels following intravenous administration. Sona's uniquely biocompatible gold nanorods demonstrated "a favorable safety profile, with tissue distribution consistent with nanoparticle pharmacokinetics and no evidence of acute or systemic toxicity." The study, conducted by a Food and Drug Administration ("FDA") Good Laboratory Practise ("GLP") compliant contract research organization, represents a critical milestone in the Company's translational development pathway and is an FDA prerequisite to initiating full human clinical trials. As a GLP study, the results will be reported to the FDA and the Company plans to continue to follow the FDA's recommendations for its full safety study program to qualify for the investigational device exemption required for broader human studies. Tillkännagivande • Feb 26
Sona Nanotech Inc., Annual General Meeting, Apr 24, 2025 Sona Nanotech Inc., Annual General Meeting, Apr 24, 2025. Location: nova scotia, halifax Canada Tillkännagivande • Oct 22
Sona Nanotech Inc. Announces the Appointment of Wayne Myles to Its Board of Directors Sona Nanotech Inc. announced the appointment of Mr. Wayne Myles, KC, FIIC, to its board of directors. An active investor and entrepreneur, Mr. Myles has served as lead counsel and strategic business advisor on more than 100 domestic and international acquisitions and sales, financings, government and regulatory affairs and licensing mandates. He has significant and diverse experience as a director of public and private companies. He also has been recognized with numerous professional achievements, distinctions and awards, including being named as one of "Canada's Top 25 Most Influential Lawyers' by Canadian Lawyer Magazine. Tillkännagivande • Sep 24
Sona Nanotech Inc. announced that it has received CAD 1.64375 million in funding On September 24, 2024, Sona Nanotech Inc. closed the transaction. The company issued 6,575,000 common shares at a price of CAD 0.25 per Share for gross proceeds CAD 1,643,750. One Insider of Sona subscribed for 400,000 of those common shares for gross proceeds of CAD 100,000. All securities issued pursuant to the Financing will be subject to a hold period until January 24, 2025. In connection with the private placement, Sona paid the Finder a cash commission of CAD 91,813 and issued 367,250 non-transferable share purchase warrants. Tillkännagivande • Sep 05
Sona Nanotech Inc. announced that it has received CAD 1.5 million in funding On September 5, 2024, Sona Nanotech Inc. closed the transaction. The company announced that it has issued 6,000,000 common shares at an issue price of CAD 1,500,000. The company paid CAD 88,750 and issued 355,000 non-transferable share purchase warrants Each Finder Warrant entitles the Finder to acquire one Share at an exercise price of CAD 0.25 until September 5, 2026. The Finder is a related party to company, a director is being indirectly a principal shareholder of the Finder, as well such director is also being a director and officer of the Finder. securities issued pursuant to the Financing will be subject to a hold period until January 6, 2025. Tillkännagivande • Jul 31
Sona Nanotech Inc. announced that it expects to receive CAD 1.5 million in funding Sona Nanotech Inc announced a private placement financing of 6,000,000 common shares at a price of CAD 0.25 per Share for gross proceeds CAD 1,500,000 on July 31, 2024. The transaction may include participation from insiders and certain other existing shareholders. The Finder will receive cash compensation equal to 7% of the gross proceeds of the Financing (5.0% for subscribers on the President's List). The Finder will also receive non-transferable share purchase warrants which will entitle the Finder to acquire such number of common shares as is equal to 7% of the number of Shares placed by the Finder. Completion of the Financing is subject to the satisfaction of certain conditions as well as the approval of the Canadian Securities Exchange. All securities issued pursuant to the Financing will be subject to a hold-period of four months and a day commencing from the closing date. Tillkännagivande • Feb 27
Sona Nanotech Inc., Annual General Meeting, Apr 26, 2024 Sona Nanotech Inc., Annual General Meeting, Apr 26, 2024. Tillkännagivande • Jan 11
Sona Nanotech Inc. Announces Retirement of Michael Gross from the Board of Directors Sona Nanotech Inc. announced that Dr. Michael Gross has retired from the Company's Board of Directors to focus on other business interests. Tillkännagivande • Oct 19
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding Sona Nanotech Inc. announced a brokered private placement of up to 3,750,000 units at CAD 0.20 per unit for gross proceeds of up to CAD 750,000 on October 18, 2023. Each unit will consist of one common share and one-half of a common share purchase warrant. Each whole warrant will be exercisable to purchase one additional common share of at a price of CAD 0.30 per share for a period of 24 months from the closing date of the transaction. The transaction will include participation from insiders and certain other existing shareholders. The completion of the transaction is subject to the satisfaction of certain conditions. All securities issued pursuant to the transaction will be subject to a hold-period of four months and a day commencing from the closing date. Tillkännagivande • Oct 13
Sona Nanotech Inc. Provides Corporate Update on Operating Activities Sona Nanotech Inc. provided an update on the status of its current operating activities, notably the development of its Targeted Hyperthermia Therapy ("THT") therapy and its rapid bovine tuberculosis prototype test. THT Program First Six-Month Accomplishments: Retained team of expert medtech consultants and experienced advisors. Engineered next generation THT light device which will be incorporated with a newly acquired Fujifilm Healthcare endoscope. Assembled a panel of leading medical experts to guide THT development strategy and preclinical study plan. Devised the preclinical safety and biocompatibility study plan needed to support an IDE application, including NCL assessments of Sona's GNRs. Secured an efficacy study of THT in multiple murine cancer models with initial results expected by year-end. Published White Paper on "Hyperthermia" photothermal therapy. Enhanced GNR manufacturing process and implemented an eQMS system. Received several unsolicited orders for nanoparticles following the release of NCL results. Hosted regular webinars to explain THT strategy and report on progress. Targeted Hyperthermia Therapy: The Company continues to progress the development of preclinical stage THT across four streams of activities. First, the Company now aims to initiate multiple preclinical studies with leading partners to build the comprehensive data set necessary to support any future regulatory applications. Among them, Sona is pleased to have secured the collaboration of the Giacomantonio Immuno-Oncology Research Group to assess THT's efficacy and the impact of associated intralesional immunomodulation in mice cancer models, with initial data expected by the end of this year. Other third-party studies will assess biocompatibility, stability, shelf life, histology, clearance and usability/human factors, amongst others, including the previously announced data provided from the multiple assessments received from the Nanotechnology Characterization Laboratory ("NCL"). Second, Sona anticipates receiving a prototype of its next generation infrared light device from medical device engineering partner Minnetronix Medical in time for its use in the Giacomantonio study. The newest version of Sona's light device has been engineered to enable the delivery of infrared light through a newly acquired Fujifilm Healthcare endoscope with real time tracking of tumor temperatures. Third, EXCITE International has secured on Sona's behalf a panel of six experts from leading medical institutions across the U.S. and Canada to validate that the target indications and intended use statements for THT, as well as its preclinical study plan, will have THT serving the purposes that both gastroenterologists and colorectal surgeons, and health care insurance providers value and will pay for, respectively. This feedback, together with guidance from its regulatory advisors, will be used in a pre-submission meeting with the U.S. Food & Drug Administration. Fourth, as part of its continuing QA/QC enhancements, Sona has implemented a Greenlight Guru eQMS quality management system and is in the process of narrowing down the list of prospective good manufacturing practice ("GMP") designated manufacturing partners to provide the materials needed for preclinical and clinical in vivo trials. Diagnostics Division Update and bTB Study Results: While Sona has strategically chosen to focus its current resources on the development of THT as it believes it can achieve a better return on investment there, work continues in its Diagnostics Division where it has rapid screening assay prototypes for both bovine tuberculosis ("bTB") and traumatic brain injuries ("TBi", "Concussions"). Sona uses its own proprietary bTB antibodies in its bTB prototype test which has recently been assessed against clinical samples of known status. Samples from cattle deemed positive for bTB, via the tuberculin skin test ("SICCT"), and samples from a bTB-free herd were both assessed in a recent study. Results show that the test generated a Positive Predictive Value ("PPV") of 80% (24/30 samples) and a Negative Predictive Value ("NPV") of 96% (29/30 samples). While the Company is pleased with these confirmatory initial results, it cautions that further clinical assessments will be required to validate the results to date. Sona intends to pursue this work with relevant institutions in order to provide the evidence necessary to support a successful commercialization of the test. The Company has paused the development of its TBi test pending the procurement of clinical sample materials appropriate for an assessment beyond the positive assessment conducted with contrived samples and to focus resources on the advancement of its THT therapy. Sona's rapid test commercialization strategy is to identify the best risk/return profile, which may include partnering and/or licensing, or other transactions. Tillkännagivande • Feb 09
Sona Nanotech Inc. Receives Technology Assessment Results from NCL Sona Nanotech Inc. announced that it has received the results of an independent assessment of its proprietary gold nanorod nanoparticles from the National Cancer Institute's Nanotechnology Characterization Laboratory (‘NCL’). The assessment included analyses of three batches of Sona's materials for microbial contamination, endotoxin levels, Beta-glucan, physiochemical characterization, and polyethylene glycol (‘PEG’) concentrations. The analyses determined that endotoxins and microbial contamination were ‘undetectable’ based on both turbidity and chromogenic limulus amebocyte lysate (‘LAL’) assays and the NCL's endotoxin limit. While beta-glucan levels varied across the samples, they were all within limits of what is normally present in the blood from dietary sources. Also, no free PEG was detected in any of the three batches of materials provided. The NCL will continue to work with Siva and Sona to conduct further studies that are anticipated to be required to support any submission for the use of Sona's gold nanorods in Siva's Targeted Hyperthermia Therapy to the US Food and Drug Administration (‘FDA’), including a quantitation of the surfactant detected in the samples. The NCL was established by the National Cancer Institute (‘NCI’) to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the FDA, and the National Institute of Standards and Technology (‘NIST’). Siva's THT path to market will involve the completion of large animal studies and the filing for an Investigational Device Exemption (‘IDE’) with the FDA in preparation for human clinical studies. Siva's management team has over 50 years of combined life sciences and medical device experience with a track record of prior successful market introductions. Tillkännagivande • Jan 27
Sona Nanotech Inc. announced that it expects to receive CAD 0.5 million in funding Sona Nanotech Inc. announced that it has entered into an definitive agreement to issue up to 5,000,000 common shares at an issue price of CAD 0.10 per share for the gross proceeds of CAD 500,000 on January 26, 2023. The company has entered into an agreement with a registered dealer to act as placement agent for the working capital financing which has agreed to pay a cash fee equal to 8% of proceeds and to issue compensation warrants entitling the placement agent to purchase that number of common shares as is equal to 8% of the common shares sold to investors introduced by the placement agent. Each compensation warrant will be exercisable into a common share at a price of CAD 0.10 per share at any time for a period of 24 months from closing. The closing of the transaction is conditional upon completing an additional equity raise for gross proceeds of at least CAD 1.0 million, or any other amount that is mutually agreed by the parties, which is expected to close by February 28, 2023.